Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

AXXZIA Inc. manufactures and distributes cosmetics. The Company produces eye creams, toners, essences, cleansers, moisturizing creams, masks, cleansing oils, and other products. AXXZIA markets its products throughout Japan.

<ul><li>Revenue increased by 17.9% YoY to JPY3.6bn, driven by strong China e-commerce sales during W11.</li><li>Operating profit rose 7.1% YoY to JPY62mn, supported by high-margin AG Drink sales in China.</li><li>SG&A expenses increased by 21.0% YoY to JPY2.6bn, with significant rises in advertising costs and personnel expenses.</li></ul>

Revenue increased by 17.9% YoY to JPY3.6bn, driven by strong China e-commerce sales during W11.Operating profit rose 7.1% YoY to JPY62mn, supported by high-margin AG Drink sales in China.SG&A expenses increased by 21.0% YoY to JPY2.6bn, with significant rises in advertising costs and personnel expenses.

AXXZIA Inc (4936 JP): Q1 FY07/26 flash update

Hamee Corp. designs and wholesales Smart Phone accessories and offers e-commerce service to sell their products. The Company also develops and provides Cloud type management platform for e-commerce businesses.

<ul><li>Hamee executed a spin-off of NE Inc. in November 2025, excluding NE from Q3 FY04/26 consolidation. </li><li>FY04/26 forecast: sales JPY21.7bn, operating profit JPY723mn, recurring profit JPY479mn, net income JPY152mn. </li><li>Commerce segment sales forecast lowered by JPY1.7bn due to weaker-than-expected 1H results and continued pressure.</li></ul>

Hamee executed a spin-off of NE Inc. in November 2025, excluding NE from Q3 FY04/26 consolidation. FY04/26 forecast: sales JPY21.7bn, operating profit JPY723mn, recurring profit JPY479mn, net income JPY152mn. Commerce segment sales forecast lowered by JPY1.7bn due to weaker-than-expected 1H results and continued pressure.

Hamee Corp (3134 JP): 1H FY04/26 flash update

Good Com Asset Co., Ltd. provides real estate services. The Company offers mansion planning, developing, and selling, as well as rent management, real estate consulting, and property and casualty insurance.

<ul><li>FY10/25 sales were JPY54.6bn (-8.7% YoY), operating profit JPY2.9bn (-46.2% YoY), net income JPY1.5bn (-54.2% YoY).</li><li>FY10/26 forecast: sales JPY79.3bn (+45.3% YoY), operating profit JPY7.7bn (+163.3% YoY), net income JPY4.5bn (+198.4% YoY).</li><li>FY10/25 saw significant SG&A expense increase due to M&A costs, advertising, and shareholder returns, impacting profitability.</li></ul>

FY10/25 sales were JPY54.6bn (-8.7% YoY), operating profit JPY2.9bn (-46.2% YoY), net income JPY1.5bn (-54.2% YoY).FY10/26 forecast: sales JPY79.3bn (+45.3% YoY), operating profit JPY7.7bn (+163.3% YoY), net income JPY4.5bn (+198.4% YoY).FY10/25 saw significant SG&A expense increase due to M&A costs, advertising, and shareholder returns, impacting profitability.

Good Com Asset (3475 JP): Full-year FY10/25 flash update

KDDI CORPORATION provides mobile communication services and sells mobile devices.  The Company also is a broadband provider.

<ul><li>Revenue for 1H FY03/26 was JPY2,963.2bn, a 3.8% YoY increase, driven by telecommunications and financial business growth.</li><li>Operating profit for 1H FY03/26 was JPY577.2bn, a 0.7% YoY increase, with Personal and Business Services growth.</li><li>Subscriptions at end-1H FY03/26 totaled 97.5mn, a 9.6% YoY increase, with IoT subscriptions up 18.4%.</li></ul>

Revenue for 1H FY03/26 was JPY2,963.2bn, a 3.8% YoY increase, driven by telecommunications and financial business growth.Operating profit for 1H FY03/26 was JPY577.2bn, a 0.7% YoY increase, with Personal and Business Services growth.Subscriptions at end-1H FY03/26 totaled 97.5mn, a 9.6% YoY increase, with IoT subscriptions up 18.4%.

Sanbio Co Ltd researches, develops, manufactures, and sells regenerative cell re lated pharmaceutical products.

<ul><li>In cumulative Q3 FY01/26, the company reported no operating revenue and an operating loss of JPY2.7bn.</li><li>The company forecasts a recurring loss of JPY4.5bn and a net loss of JPY4.0bn for FY01/26.</li><li>R&D expenses increased to JPY2.8bn, reflecting sales preparation and manufacturing costs for AKUUGO® approval changes.</li></ul>

In cumulative Q3 FY01/26, the company reported no operating revenue and an operating loss of JPY2.7bn.The company forecasts a recurring loss of JPY4.5bn and a net loss of JPY4.0bn for FY01/26.R&D expenses increased to JPY2.8bn, reflecting sales preparation and manufacturing costs for AKUUGO® approval changes.

SanBio Co Ltd (4592 JP): Q3 FY01/26 flash update

Our report is an authoritative Owner’s Manual on the company.
- A vital piece in the investor’s toolbox, our report allows you to uncover the essence of the business
- We pinpoint strengths and weaknesses; discuss strategy
- Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue

We offer our research as a service for Japanese corporates.
- Our in-depth reports allow them to better inform investors by presenting an unbiased third-party view of business fundamentals
- Our reports do not offer investment opinions and are free for all investors

We start our coverage with a substantial core report.
- We continuously update this report to reflect earnings, news flow, and any material developments
- We thoroughly interview management on a quarterly basis